All content and product details on this site are for educational purposes only. Products are for in-vitro studies (performed outside the body) and not FDA-approved for medical use. Any introduction into humans or animals is prohibited by law.
Categories
Recent Posts
CJC-1295 Peptide Research: GHRH Analog and Growth Hormone
Explore CJC-1295, a GHRH analog originally developed as an investigational compound. Studies have measured its effects on growth hormone and IGF-1 levels.
PP-TS1: GHRH Analog Research
PP-TS1 is a growth hormone-releasing hormone analog studied for its stability, GHRH-receptor pharmacology and GH/IGF-1 responses. A summary of the published literature.
Peptides and Aging Biology: A Research Overview
Peptides are gaining attention as research tools in aging biology. These short chains of amino acids regulate cellular repair, inflammation, and hormonal balance, processes that are studied in research on age-related conditions. Recent research has examined their interactions with aging mechanisms. This article explores peptides’ role in aging biology research and the challenges facing this field.
Ipamorelin Peptide: Growth Hormone Secretagogue Research
Brief Overview/Summary
Explore research on Ipamorelin peptide, a pentapeptide, and its selective growth hormone secretion mechanisms, and ghrelin receptor (gh) activation through scientific studies.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that has attracted attention in growth hormone (GH) research [1]. It belongs to the class of growth hormone-releasing peptides (GHRPs) and stimulates the release of GH from the pituitary gland through the GH secretagogue receptor [1][2].
Ipamorelin is frequently selected in endocrine research because of its selectivity. In the study that first described it, ipamorelin released GH with a potency and efficacy similar to GHRP-6, but, unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol levels in swine beyond those seen after GHRH stimulation [1].
Through the GH secretagogue receptor, which is also the receptor for the stomach-derived hormone ghrelin, ipamorelin acts as a ghrelin mimetic [2][3][4]. In the same swine studies, none of the GH secretagogues tested affected FSH, LH, prolactin or TSH levels [1].
Ipamorelin is still being researched, and interest in it stems from reports that it acts on GH release without significant effects on the other pituitary and adrenal hormones that were measured [1].
Mechanism of Action of Ipamorelin Peptide.
Ipamorelin stimulates the release of endogenous growth hormone. Pharmacological profiling with GHRP and growth hormone-releasing hormone (GHRH) antagonists showed that ipamorelin, like GHRP-6, releases GH through a GHRP-type receptor rather than through the GHRH receptor [1]. This receptor, the GH secretagogue receptor (GHS-R), is expressed in the pituitary and the hypothalamus [2].
In primary rat pituitary cells, ipamorelin released GH with a potency and efficacy similar to GHRP-6 [1]. Its lack of effect on ACTH and cortisol is the reason it was described as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH [1].
Research Evidence
Published research on ipamorelin is largely preclinical. In adult female rats, ipamorelin increased the longitudinal bone growth rate and body-weight gain, without changing total IGF-I levels or serum markers of bone formation and resorption [5].
In a 12-week study in young adult female rats, ipamorelin and GHRP-6 increased body weight and bone mineral content measured by dual X-ray absorptiometry; the authors attributed this to larger bone dimensions rather than to higher volumetric bone mineral density [6].
In adult rats given glucocorticoids, ipamorelin was studied for its effect on the glucocorticoid-induced decrease in bone formation [7].
Research Applications
Ipamorelin was developed in the 1990s within a chemistry programme on peptides for hormones, specifically GHRPs, and was identified within a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1 [1]. A later series of potent GH-releasing peptides was derived from its structure [8].
Endocrine research distinguishes two receptor systems that trigger GH release. GHRH acts through its own receptor, while GHRPs such as ipamorelin, GHRP-2 and GHRP-6 act through the GH secretagogue receptor [1][2]. Somatotropes are the pituitary cells that produce and secrete GH.
As a member of the GHRP class, ipamorelin's distinguishing feature in published studies is selectivity. GHRP-6 and GHRP-2 increased ACTH and cortisol levels in swine, whereas ipamorelin did not, even at exposure levels far above those needed for GH release [1].
Research on Ipamorelin has examined several areas, some of which are as follows:
Bone growth and bone mineral content in rat models [5][6][7].
Gastrointestinal motility: as a ghrelin-receptor agonist, ipamorelin was studied in a rat model of postoperative ileus, in which gastrointestinal transit was measured [4].
Pancreatic islet function: in pancreatic tissue fragments from normal and diabetic rats, ipamorelin evoked insulin release through calcium-channel and adrenergic pathways [9].
Future Research Perspectives
The continued study of Ipamorelin may yield further insights into its potential role within biological systems. Future research might focus on identifying additional receptor interactions, clarifying its possible impact on intracellular signaling pathways, and determining its influence on various physiological models. Moreover, investigations might explore its comparative impact relative to other growth hormone secretagogues to establish its distinctive characteristics in scientific studies.
While the research landscape surrounding Ipamorelin remains in development, its potential implications in understanding fundamental biological processes continue to garner interest. By leveraging its unique properties, researchers may uncover new dimensions of growth hormone regulation and its broader significance in cellular physiology.
References
Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. https://doi.org/10.1530/eje.0.1390552
Howard, A. D., Feighner, S. D., Cully, D. F., Arena, J. P., Liberator, P. A., Rosenblum, C. I., et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974-977. https://doi.org/10.1126/science.273.5277.974
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656-660. https://doi.org/10.1038/45230
Venkova, K., Mann, W., Nelson, R., & Greenwood-Van Meerveld, B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 329(3), 1110-1116. https://doi.org/10.1124/jpet.108.149211
Johansen, P. B., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113. https://doi.org/10.1054/ghir.1999.9998
Svensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 165(3), 569-577. https://doi.org/10.1677/joe.0.1650569
Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272. https://doi.org/10.1054/ghir.2001.0239
Ankersen, M., Johansen, N. L., Madsen, K., Hansen, B. S., Raun, K., Nielsen, K. K., et al. (1998). A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of Medicinal Chemistry, 41(19), 3699-3704. https://doi.org/10.1021/jm9801962
Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinology Letters, 25(6), 403-406. PMID: 15665799
Read more about peptides
Adamax Peptide: A Nootropic Peptide Option?
Explore research on Adamax peptide, a modified form of Semax, and published Semax studies on BDNF signalling and neuronal function
Understanding NAD⁺: Function and Current Research
Explore research on NAD+ (Nicotinamide Adenine Dinucleotide) and Nicotinamide Phosphoribosyltransferase